Hairy Cell Leukemia Marker Inhibitors
Hairy cell leukemia marker inhibitors are a class of chemical compounds that specifically target and modulate the biological markers associated with hairy cell leukemia (HCL), a rare type of chronic B-cell leukemia. These markers are often cell surface proteins, enzymes, or other biomolecules that are uniquely expressed or overexpressed in hairy cells, which are abnormal B lymphocytes characterized by cytoplasmic projections. Hairy cell leukemia marker inhibitors are designed to interfere with the normal functioning or expression of these markers, altering signaling pathways or cellular processes specific to the malignant cells. By disrupting these pathways, these inhibitors can potentially modulate the behavior of hairy cells, affecting their proliferation, survival, or other cellular activities.
These inhibitors typically work by binding to specific molecular targets associated with hairy cell leukemia markers, such as certain enzymes or receptors, blocking or altering their normal function. This binding may induce conformational changes in the target proteins, affect signal transduction cascades, or inhibit enzymatic activity. As these inhibitors are designed to interact with unique features of hairy cell markers, they exhibit high specificity towards the cells exhibiting these markers, minimizing off-target effects. Hairy cell leukemia marker inhibitors are often investigated for their ability to modulate various biochemical pathways relevant to the progression and maintenance of the disease, contributing to a deeper understanding of the molecular mechanisms that define hairy cell leukemia.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
2-Chloro-2′-deoxyadenosine | 4291-63-8 | sc-202399 | 10 mg | $144.00 | 1 | |
2-Chloro-2′-deoxyadenosine may disrupt the DNA repair and synthesis in HCL cells, leading to apoptosis and thus potentially decreasing the expression of HCL markers. | ||||||
Pentostatin | 53910-25-1 | sc-204177 sc-204177A | 10 mg 50 mg | $175.00 $702.00 | 5 | |
By inhibiting adenosine deaminase, Pentostatin could lead to an accumulation of deoxyadenosine, causing cell death and potentially reducing HCL marker levels. | ||||||
Bendamustine | 16506-27-7 | sc-357294 | 100 mg | $300.00 | ||
Bendamustine may induce intra-strand DNA crosslinks, resulting in cell cycle arrest and subsequent apoptosis, thereby possibly decreasing marker expression in HCL. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
As a BRAF V600E kinase inhibitor, Vemurafenib could inhibit the MAPK pathway, leading to reduced proliferation of HCL cells and a consequent downregulation of HCL markers. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
CAL-101 targets PI3K delta, potentially leading to reduced survival signaling in HCL cells, which may result in a decrease in the expression of HCL markers. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Through MEK inhibition, Trametinib might reduce the MAPK pathway signaling, leading to decreased survival and proliferation of HCL cells and lower HCL marker expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
By inhibiting mTOR, Rapamycin could reduce protein synthesis and cell proliferation, which might lead to a reduction in the expression of markers associated with HCL. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
ABT-199 selectively inhibits BCL2, an anti-apoptotic protein, potentially leading to programmed cell death in HCL cells and subsequent downregulation of HCL markers. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib inhibits CDK4 and CDK6, potentially leading to a halt in cell cycle progression in HCL cells, which could result in decreased expression of HCL markers. | ||||||
R788 | 901119-35-5 | sc-364597 sc-364597A | 2 mg 50 mg | $405.00 $4000.00 | 2 | |
By inhibiting SYK kinase, R788 might diminish B-cell receptor signaling, leading to reduced survival of HCL cells and potentially lower expression of HCL markers. | ||||||